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Amyloid Precursor Proteins Inhibit
Heme Oxygenase Activity and Augment
Neurotoxicity in Alzheimer’s Disease
Introduction
Alzheimer’s disease (AD) is characterized by the pres-
ence of amyloid plaques and tangles in the brains of
affected individuals (Price and Sisodia, 1998). The princi-
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lytic processing of amyloid precursor proteins (APP) by1 Department of Neuroscience
b and g secretases, leading to the formation of amy-2 Department of Anesthesiology/Critical
loid-b (Ab) peptides (Selkoe, 1996). Of the two majorCare Medicine
forms, the 42 amino acid peptide (Ab42) is more closely3 Department of Medicine, Division
linked to AD pathophysiology than the 40 amino acidof Gastroenterology
form Ab40 (Price and Sisodia, 1998). Familial Alzhei-4 Department of Pathology
mer’s disease (FAD), reflecting mutations in APP and5 Department of Pharmacology
presenilins, is associated with augmented the formationand Molecular Sciences
of the neurotoxic Ab42 (Jarrett and Lansbury, 1993;6 Department of Psychiatry
Yankner, 1996), which can directly elicit brain damageThe Johns Hopkins University
(Hardy, 1997a, 1997b; Younkin, 1995).School of Medicine
Physiological functions of APP have not been fully725 North Wolfe Street
defined. Though some groups have postulated that APPBaltimore, Maryland 21205
may have a neuroprotective action (Mucke et al., 1996),7 Department of Neuropathology and Neuroscience
this hypothesis is still controversial (White et al., 1998).Faculty of Pharmaceutical Science
APP is a member of a multigene family that contains atUniversity of Tokyo
least two other members known as amyloid precursor-Tokyo 113
like protein (APLP)-1 and -2 (Wasco et al., 1992, 1993;Japan
Sprecher et al., 1993; Slunt et al., 1994). APLP isoforms8 Department of Neurobiology
contain most of the domains and motifs of APP but lackPharmacology and Physiology
the Ab region. Structural similarities between APP andThe University of Chicago
APLP and the viability of mice with ablated APP (ZhengChicago, Illinois 60637
et al., 1995) and APLP2 (von Koch et al., 1997) have
suggested that APLP functionally compensate for some
physiologic functions of APP (Crain et al., 1996; McNa-
mara et al., 1998).
Heme oxygenase (HO) was first characterized as anSummary
enzyme that degrades heme from aging red blood cells
(Maines, 1997). This isoform of HO, HO1, is induced byAmyloid precursor protein (APP) generates the b-amy-
a large number of stimuli and is also designated heatloid peptide, postulated to participate in the neurotox-
shock protein-32 (HSP-32) (Shibahara et al., 1985). Aicity of Alzheimer’s disease. We report that APP and
second isoform, HO2, is not inducible and displays high-APLP bind to heme oxygenase (HO), an enzyme whose
est concentrations in the brain (Rotenberg and Maines,product, bilirubin, is antioxidant and neuroprotective.
1990). In catabolizing heme, HO gives rise to three prod-The binding of APP inhibits HO activity, and APP with
ucts, carbon monoxide (CO), iron, and biliverdin. Biliver-
mutations linked to the familial Alzheimer’s disease
din is immediately reduced by biliverdin reductase to
(FAD) provides substantially greater inhibition of HO bilirubin, while CO functions as a neurotransmitter in the
activity than wild-type APP. Cortical cultures from autonomic nervous system (Zakhary et al., 1997) and
transgenic mice expressing Swedish mutant APP have possibly in the brain (Verma et al., 1993; Maines, 1997).
greatly reduced bilirubin levels, establishing that mu- HO activity protects against oxidative stress (Abraham
tant APP inhibits HO activity in vivo. Oxidative neuro- et al., 1995; Lee et al., 1996; Dennery et al., 1997; Poss
toxicity is markedly greater in cerebral cortical cul- and Tonegawa, 1997b). Recent studies indicate that
tures from APP Swedish mutant transgenic mice than HO1 is cytoprotective by increasing iron transport out
wild-type cultures. These findings indicate that aug- of cells (Ferris et al., 1999), accounting for iron accumu-
mented neurotoxicity caused by APP–HO interactions lation in tissues of HO1 and HO2-deficient mice (Poss
may contribute to neuronal cell death in Alzheimer’s and Tonegawa, 1997a; Dennery et al., 1998). Bilirubin
disease. has antioxidant activity (Stocker et al., 1987), and re-
cently we have found that bilirubin appears to be a
physiologic neuroprotectant (Dore´ et al., 1999a, 1999b).
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Figure 1. Interaction of HO and APP/APLP
(A) Determination of the binding domain of
APLP1 to HO2 by yeast two-hybrid analysis.
The expression vector encoding rat HO2
C-terminal domain (169–296) fused to the Gal
4 DNA binding domain was cotransformed
into yeast Y190 cells with the indicated dele-
tion mutants of APLP1 fused to the Gal 4
activation domain expression vector. Plus
signs represent activation of HIS3 and b-gal
reporters (,1 hr). Plus-minus signs represent
slow growth on a plate lacking histidine and
weak b-gal activities (,8 hr).
(B) In vivo interaction of APP with HO1 and
HO2. HEK293 cells were transiently trans-
fected with human HO constructs and (His)6-
tagged APLP1 (APLP1 His) or full-length APP/
APLP2 constructs (APP695, APP770, and
APLP2). After 40 hr, extracts were prepared
and immunoprecipitated with anti HO anti-
body. Coprecipitated APP was detected by
immunoblot analysis using an anti-(His)6 or
anti-APP/APLP2 monoclonal antibody (22C11).
The arrow indicates APLP1-His.
(C) Specificity of the interaction of APP with
HO1. HEK293 cells were transfected with
HO1 expression vector and various APP con-
structs. APP695 (1–477) and APP770 (1–552)
are soluble deletion mutants that have the
signal peptide on the N terminus and are lo-
calized into the lumenal side of the ER.
APP695 (46–477) and APP770 (46–552) lack
the signal peptide on the N terminus and are
localized in the cytosol. After 40 hr, extracts
were prepared and immunoprecipitated with
anti-HO1 antibody. Coprecipitated APP was
detected by immunoblot analysis using the
anti-APP monoclonal antibody.
(D) Subcellular fractionation of mouse neuro-
blastoma (N2A cells) was accomplished using
0%–26% Iodixanol-based linear density gra-
dient as indicated in Experimental Proce-
dures. Eighteen fractions, from top to bottom,
were collected. The density of each fraction
was estimated from refractory index and was
linear throughout the gradient. Aliquots of
each fraction were run on 8%–15% gradient
SDS–PAGE and analyzed by immunoblotting
with anti-HO2, anti-APP (CT15), and anti-
KDEL antibodies. Anti-KDEL recognizes the
ER luminal markers, the Grp94, and BiP.
family members leading to inhibition of HO activity. Mu- rived from rat cerebral cortex, we identified five different
tant APP associated with FAD inhibit HO activity signifi- positive clones and subsequently focused on APLP-1
cantly more than wild-type APP. In cortical cultures from (Figure 1). To eliminate the possibility that only HO or
APP Swedish mutant mice, bilirubin levels are substan- APLP was necessary to activate transcription of GAL4
tially diminished, while oxidative stress-induced neuro- in yeast, we monitored growth on histidine-minus plates
toxicity is markedly increased. These findings suggest and b-galactosidase (b-gal) activity following transfor-
that reduced neuroprotective activity of HO, resulting mation of yeast with HO or APLP alone or in combination
from APP-HO interaction, may participate in the neuro- with another irrelevant construct (see Experimental Pro-
toxicity of AD. cedures). In these experiments, we were able to detect
interaction in yeast only following transformation of both
HO and APLP (data not shown). To examine the preciseResults
portions of HO2 and APLP-1 required for the interaction,
we conducted yeast two-hybrid studies with constructsHO Interacts with and Is Colocalized
of different lengths. Truncation of APLP-1 reveals thatwith APP/APLP
interaction with HO2 is restricted to an acidic domain,We conducted a yeast two-hybrid analysis employing
encoding amino acids 237–271, near the zinc bindinga portion of HO2 (amino acids 169–296) as “bait.” After
screening five million colonies from a cDNA library de- site. APP and APLP-1 share 36% amino acid identity
Amyloid Precursor Proteins Inhibit Heme Oxygenase
463
and 41% amino acid similarity over this region. Amino ures 2A and 2B). To confirm permeabilization of the ER
acids 169–296 of HO2, which are closely associated with membranes with saponin, we stained cells for Grp78,
its catalytic domain, are required for interaction with which is localized to the lumen of the ER (Doan et al.,
APLP, while a construct containing the N-terminal por- 1996). Grp78 staining is nearly absent in digitonin-
tion (amino acids 2–143) is inactive (data not shown). treated cells, while staining is evident in saponin-treated
Using immunoprecipitation, we compared interac- cells (Figures 2C and 2D). Immunofluorescence for HO2
tions of HO1 and HO2 with two physiologic isoforms of is strikingly similar to that seen with Grp78 antibodies,
APP, APP695, and APP770 (Figures 1B and 1C). In these with no staining evident in digitonin-treated prepara-
experiments, HEK293 cells were transiently transfected tions but clear staining in the saponin-treated cells (Fig-
with cDNA encoding the various forms of APP, and some ures 2E and 2F).
of these were cotransfected with HO1 or HO2 cDNA. To compare the intracellular localization of APP and
Immunoprecipitation was conducted with antisera to HO2 in brain tissue without transfection, we conducted
HO1 or HO2, and the presence of APP in the immunopre- immunohistochemical staining with primary cultures of
cipitates was evaluated by immunoblotting. In all cases, rat cortical neurons. HO2 and APP staining in neurons
APP are precipitated only in cells transfected with HO1 reveals overlapping subcellular distributions consistent
or HO2. These immunoprecipitation findings confirm the with colocalization of the two proteins (Figures 2G–2I).
protein–protein interactions first identified in yeast two- To ascertain whether HO2 and APP exist as a complex
hybrid analysis. in brain under native conditions, we immunoprecipi-
In order for HO-APP interactions to be physiologically tated HO2 from rat brain extracts and monitored co-
relevant, the two proteins should be in the same subcel- precipitation of APP by Western blot. As shown, APP
lular compartment. APP is cotranslationally translocated coprecipitates upon immunoprecipitation of HO2 but is
into the endoplasmic reticulum via its signal peptide and not detected in immunoprecipitates generated using an
then undergoes maturation during passage through the anti-calnexin antibody (Figure 2J). We also detect co-
Golgi. A minor percentage of mature APP is transported precipitation of HO2 in immunoprecipitates of APP (data
to the plasma membrane via secretory vesicles. Thus, not shown). In addition, we immunoprecipitated HO2
the majority of APP remains in the Golgi (Selkoe, 1996) from mouse brain extracts prepared from wild-type and
and endoplasmic reticulum (ER), where the acidic do- HO22/2 mice. In these experiments, we detect coprecipi-
main of APP is within the lumen (Selkoe, 1996). HOs are tation of APP in extracts derived from wild-type but not
ER proteins with an N-terminal domain anchored to the HO22/2 brains (data not shown). Thus, coprecipitation
ER by a single transmembrane domain at the extreme C studies, subcellular fractionation, and immunofluores-
terminus (Maines, 1997). However, the transmembrane cence studies all indicate that the N-terminal region of
topology of HO has not been definitively established HO2 is located within the ER lumen, where it interacts
(Hino et al., 1979; Yoshida and Sato, 1989). To determine with the acidic portion of APP.
if HO and APP are located in the same subcellular com-
partment, we conducted immunoprecipitation experi- HO1 and HO2 Expression Do Not Affect
ments with native or truncated forms of APP695 or Ab Peptide Production
APP770 (Figure 1C). C-terminal truncation transforms To ascertain whether HO1 or HO2 influence the pro-
APP from a particulate ER protein to a soluble lumenal cessing of APP into the Ab peptides, we employed
protein, while truncation of the signal peptide results in HEK293 cell lines stably transfected with CPR (293/
a cytoplasmic localization of APP. We find that coimmu- CPR), which provides electron donation for HO activity
noprecipitation of APP/HO persists following truncation
(Maines, 1997), and cells stably transfected with HO1
of the transmembrane portion of APP, while truncation
(293/CPR-HO1) or HO2 (293/CPR-HO2). These cell lines
of the signal peptide abolishes interaction of APP with
manifest 6- to 10-fold augmentation of HO1 or HO2 byHO (Figure 1C).
both Western blot and enzyme activity. These levels areTo further define the subcellular localization of APP
similar to endogenous levels in tissues in which HO1 orand HO, we monitored the distribution of APP and HO
HO2 are enriched (Maines, 1997). Each line was tran-following fractionation of membranes from mouse neu-
siently transfected with cDNA encoding APP695 orroblastoma (N2a) cells on Iodoxanol-based linear den-
APP770, and levels of Ab in the conditioned mediumsity gradients (Kim et al., 2000). HO2 and APP comigrate
were quantified using a two-site ELISA (Tomita et al.,in fractions (10–13), coinciding with ER lumenal markers
1997) (Table 1). Expression of HO1 or HO2 does notGRP94 and BiP (Figure 1D).
significantly alter levels of secreted Ab40 or Ab42. More-In other experiments, we monitored HO immunofluo-
over, the ratio of Ab42 to total Ab is essentially the samerescence in 293/cytochrome P450 reductase (CPR)-HO2
in 293/CPR-HO1 or 293/CPR-HO2 cells as it is in 293/cells following selective permeabilization of the plasma
CPR cells. Thus, there is no significant effect of HO1 ormembrane with digitonin or complete membrane per-
HO2 on the conversion of APP to Ab peptides in thesemeabilization with saponin (Otto and Smith, 1994) (Fig-
cells.ures 2A–2F). For these experiments, we chose to monitor
HO2 localization since under physiologic conditions
APP/APLP Diminish HO Activity and AccentuateHO2 is the only HO isoform expressed in the brain. To
Hemin Toxicityconfirm permeabilization of the plasma membrane, we
To ascertain the influence of APP interaction upon HOmonitored immunostaining for the C terminus of cal-
activity, we utilized 293/CPR-HO1 and 293/CPR-HO2nexin, which is located on the cytosolic side of the ER
cells transiently transfected with cDNA encoding APP(Ou et al., 1993). Calnexin staining appears similar fol-
lowing either digitonin or saponin permeabilization (Fig- or green fluorescent protein (GFP) as a control. The data
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Figure 2. Immunocytochemical Analysis of
HO and APP
(A–F) Immunocytofluorescent staining of se-
lectively permeabilized 293/CPR-HO2 cells.
Cells were fixed and permeabilized with ei-
ther digitonin or saponin. Cells were then
stained with either an anti-calnexin C termi-
nus polyclonal antibody (anti-calnexin CT) or
costained with an anti-KDEL monoclonal an-
tibody and an anti-HO2 polyclonal antibody
(SPA897). The bar represents 10 mm.
(G–I) Primary cultured rat cortical neurons
were stained by an anti-HO2 polyclonal anti-
body or an anti-APP/APLP2 monoclonal anti-
body (22C11). Colocalization was conducted
by confocal microscopy. The bars represent
50 mm.
(J) APP/APLP2 and HO2 complex are detect-
able in rat brain extracts. An anti-HO2 anti-
body (OSA200) specifically coprecipitates
APP/APLP2, while comparable amounts of an
anti-calnexin CT antibody fail to coprecipitate
APP.
shown are derived from measurements of HO activity In an effort to assess in vitro the influences of purified
APP on HO activity, we incubated purified His-taggedfollowing a 5 min incubation because, in other time
course experiments, we determined that the 5 min time APP695 or APLP with Triton X-100 solubilized extracts
of cells stably transfected with HO1 or HO2 and cyto-point was reliably in the linear range of enzyme activity
under our experimental conditions. Mock transfection chrome P450 reductase. Concentration of APP, APLP,
HO1, HO2 were approximately stoichiomatric. We doand transfections with GFP cDNA have no influence on
HO1 or HO2 activity in cell lysates, while APP695 and not detect inhibition of HO1 or HO2 catalytic activity
under these conditions (data not shown). There are sev-APP770 cDNA transfections reduce HO1 and HO2 activ-
ity by 25%–35% (Figure 3A). Expression of HO1 and eral possible reasons for failure to demonstrate inhibi-
tion. Preparation of APP and APLP utilized denaturingHO2 is not changed by the transfections (Figure 3A,
inset). Since the efficiency of transfection, as estimated conditions followed by refolding, which may not have
reconstituted two optimal conformations for HO inhibi-by cell counting using GFP, is about 60%, the extent
of enzyme inhibition in the cells that are successfully tion. Interactions of APP/APLP and HO may require
physiologic juxtaposition of two proteins on intracellulartransfected is likely to be substantially greater than ob-
served values. In these experiments, cells are lysed in membranes. Such interaction may not be readily recon-
stituted in vitro.glycerol containing buffer to preserve protein–protein
interaction. In other experiments, where cells are lysed in Cells expressing HO are highly resistant to hemin tox-
icity (Abraham et al., 1995), while fibroblasts from HO1-buffer without glycerol, we often fail to detect significant
inhibition of HO activity, suggesting that the HO–APP deficient mice are sensitive to hemin (Poss and Tone-
gawa, 1997b). Since hemin can induce HO1 mRNA andinteraction may be labile. Because the lysis of cells,
required to conduct HO enzymatic assays, may disrupt protein synthesis in a variety of cell types (Maines, 1997),
we examined HO1 and HO2 protein content by Westernendogenous protein–protein interactions, we sought to
assess HO activity in intact cells using hemin toxicity. blot in hemin-treated cells. No increase of HO1 protein
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Table 1. Amyloid-b Production in the 293/CPR, 293/CPR-HO1, and 293/CPR-HO2 Cells
Ab Production (pmol/mg cell protein) Ratio
cDNA Cell Line Ab40 Ab42 (Ab42/Ab40 1 Ab42)
APP695 293/CPR 15.2 6 0.8 1.55 6 0.09 9.7%
293/CPR-HO1 14.9 6 1.2 2.03 6 0.04 12.0%
293/CPR-HO2 15.7 6 0.4 1.68 6 0.02 9.8%
APP770 293/CPR 12.6 6 0.8 1.40 6 0.02 10.0%
293/CPR-HO1 13.7 6 0.5 1.70 6 0.14 11.4%
293/CPR-HO2 12.8 6 0.1 1.38 6 0.11 9.8%
expression is observed with hemin administration in any cells (Figure 3C). These findings establish that hemin
toxicity reflects HO activity.of the three cell lines (Figure 3D). To determine whether
APP/APLP mediated inhibition of HO activity affects tox- Next, we evaluated the influence of transient transfec-
tion of APP695, APP770, APLP1, and APLP2 in 293/CPR,icity in intact cells, we monitored cell death following
treatment of cells with hemin by Trypan blue exclusion. 293/CPR-HO1, or 293/CPR-HO2 cells. Transfection with
GFP has no influence on hemin toxicity in 293/CPR-HO1In 293/CPR cells, hemin is highly toxic with 40% killing
of cells evident at 50 mM (Figure 3C). In contrast, 293/ and 293/CPR-HO2 cells (Figures 3E and 3F). By contrast,
APP695, APP770, APLP1, or APLP2 transfections allCPR-HO1 and 293/CPR-HO2 cells are markedly pro-
tected with only 10%–20% cell death elicited at 200 mM markedly increases hemin toxicity (Figures 3E and 3F).
In wild-type cells or CPR cells without HO overexpres-hemin, a concentration that kills over 80% of 293/CPR
Figure 3. APP and APLP Inhibit HO Catalytic
Activity
(A) HEK293/CPR-HO1 or (B) 293/CPR-HO2
cells were transfected with APP expression
vectors by electroporation. After 20 hr, cells
were harvested and disrupted by freeze-
thaw. Then, HO activities in 12 mg (293/CPR-
HO1) or 20 mg (293/CPR-HO2) of cell extracts
were determined using [55Fe]hemin as a sub-
strate. Insets show the expression of HO1 or
HO2 in the cells transfected with GFP (lane
1), APP695 (lane 2), APP770 (lane 3), APLP1
(lane 4), or APLP2 (lane 5) cDNA.
(C) Survival of cells overexpressing HO1 or
HO2 exposed to hemin. HEK293/CPR, 293/
CPR-HO1, or 293/CPR-HO2 cells were ex-
posed for 20 hr to several concentrations of
hemin. Cell survival was determined by Try-
pan blue exclusion.
(D) HO expression after 20 hr exposure of the
cells to hemin. HO1 and HO2 protein levels
in 10 mg of cell extracts were determined by
immunoblot analysis. The numbers indicate
concentrations of hemin (0, 50, or 100 mM).
Induction of endogenous HO1 was not de-
tected in these cell lines.
(E and F) Survival of 293/CPR-HO1 or 293/
CPR-HO2 cells transfected with APP695,
APP770, APLP1, or APLP2 expression vec-
tors. Cells were cultured for 5 hr after trans-
fection and then exposed for 20 hr to hemin
(0, 50, 100, 200 mM). Results are mean of
duplicate determinations and the experi-
ments were repeated three times with similar
results.
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Figure 4. APP and APLP Inhibit HO in Intact Cells
To monitor HO activity in intact cells, cell viability of 293/CPR-HO2 cells transfected with various APP/APLP-1 deletion constructs was
monitored in response to hemin. Schematic representation of APP/APLP-1 deletion mutants shows signal peptide (Signal), the zinc binding
site (Zn), the acidic domain (Acidic), the Kunitz protease inhibitor domain (KPI), the transmembrane domain (TM), and the Ab fragment (Ab).
The a and b cleavage sites are indicated by arrowheads. The cells were cotransfected with a LacZ expression vector (1.5 mg) and membrane-
bound APP constructs (3 mg), APP (3 mg), or the other soluble APP deletion constructs (20 mg) by electroporation. After transfection, cells
were cultured for 5 hr, and hemin was added into the culture medium at a final concentration of 100 mM. After 12 hr of incubation with hemin,
cell viability was determined by a b-gal assay. The values represent b-gal activity relative to the same cells without hemin treatment (percent
of control). Results are mean of triplicate determinations and the experiments were repeated three times with similar results.
sion, we do not detect in increased hemin toxicity follow- N-terminal signal peptide in MycAPP(46–477) disrupts
the subcellular localization of APP and markedly attenu-ing APP transfection establishing that APP transfection
mediates the increased toxicity through inhibition of HO. ates the increased hemin toxicity. While three different
APLP1 constructs provide substantial increases in he-
min toxicity, APLP1(1–223) lacks the acidic domain andInhibition of HO Activity in Intact Cells by APP/APLP
Requires the Acidic Domain but Not again has substantially attenuated activity (Figure 4).
the Transmembrane Region
We employed several truncations of APP/APLP to ascer- Familial Alzheimer’s Disease Mutants Exhibit
Increased HO Inhibitiontain the sequence required for regulation of HO activity
in intact cells (Figure 4). In these experiments, 293/CPR- FAD has been associated with distinct mutations of APP
(Hardy, 1997b). We wondered whether mutant forms ofHO2 cells were cotransfected with APP and LacZ con-
structs. After exposure to hemin, cell viability was moni- APP influence HO activity differently than the wild type.
We examined the Swedish mutation (K670N/M671L), thetored by b-gal activity in cell lysates. In this way, we can
selectively monitor transfected cells and easily quantify Dutch mutation (E692Q), and the three London muta-
tions (V717G, V717F, V717I). We transiently transfectedcell death. Since APP695 and APP770 show similar ac-
tivities, the two alternatively spliced exons in APP770 the mutants or wild-type APP695 into 293/CPR-HO1 or
293/CPR-HO2 cells. Expression of each of the five FADare not required for activity. Deletion of the C-terminal
portion of APP (constructs aAPP695s and bAPP695s) mutant APP provides 45%–50% inhibition of HO1 and
HO2 activity, about twice that elicited by wild-type APPdoes not significantly affect the increase in hemin toxic-
ity. Thus, the Ab peptide is not required for augment- (Figures 5A and 5B). To ensure that the total expression
of APP/APLP was similar following all transfections, weed hemin toxicity (Figure 4). While APP695D305–590,
APP695(1–477), and APP695(1–305) retain significant monitor APP/APLP expression by Western blot. Total
APP/APLP expression is similar following transfectionactivity, APP695D198–590 and APP695(1–197) lack the
acidic domain and have markedly reduced activity. Of of the five FAD mutant forms and wild-type APP695
(Figure 5C).note, APP695D305–590 does contain the transmem-
brane domain, indicating that the transmembrane do- To assess the effect of the FAD mutations on hemin
toxicity in intact cells, we cotransfected a LacZ con-main is not sufficient to interact with HO. Deletion of the
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Figure 5. APP Mutations Associated with
FAD Augment HO Inhibition
(A and B) Inhibition of HO activity by APP.
293/CPR-HO1 or 293/CPR-HO2 cells were
transfected with the wild-type APP695 or FAD
mutant expression vectors by electropora-
tion. After 20 hr, HO activities in 12 mg (293/
CPR-HO1) or 20 mg (293/CPR-HO2) of cell
extracts were determined using [55Fe]hemin
as a substrate. A single asterisk indicates p ,
0.05, while a double asterisk indicates p ,
0.01.
(C) Expression of APP695 in the transfected
293/CPR-HO2 cells were determined in 10 mg
of cell extracts by immunoblot analysis using
an anti-APP monoclonal antibody (22C11). Of
note, mock-transfected cells do not display
any immunoreactivity under these condi-
tions, though longer exposures of the blots
do reveal modest baseline APP/APLP immu-
noreactivity.
(D and E) Survival of 293/CPR-HO1 and CPR-
HO2 cells transfected with wild-type or FAD
mutant APP. HEK293/CPR-HO1 cells were
cotransfected with 1.5 mg of a LacZ expres-
sion vector and 3 mg of APP695 constructs.
293/CPR-HO2 cells were transfected 0.5 mg
of the LacZ construct and 1 mg of APP con-
structs. After treatment with hemin, cell via-
bility was determined by a b-gal assay. Re-
sults are mean of duplicate determinations
and the experiments were repeated three
times with similar results.
struct with the various APP constructs and monitored tyl acetate (PMA), a concentration that reproducibly
stimulates bilirubin accumulation in such cultures (Dore´cell death. The Swedish, Dutch, and the London (V717G)
mutations all are associated with greater hemin-elicited et al., 1999a). PMA treatment markedly augments biliru-
bin staining in the nontransgenic littermate cultures butcell death than the wild-type APP695 or APP770 (Figures
5D and 5E). These data indicate that FAD-associated has no effect in cultures from transgenic littermates (Fig-
ure 6). Since PMA may have effects other than activationmutations result in greater inhibition of HO activity and
augmented hemin toxicity. of HO, we induced neurotoxicity with H2O2 in wild-type
and HO22/2 cortical cultures. Pretreatment of the cul-
tures with PMA (0.1 mM) could offer complete neuropro-HO Inhibition and Oxidative Neurotoxicity Are
Increased in Cortical Cultures from APP tection for wild-type neurons, whereas no significant
protection occurred in the HO22/2 cells (data not shown)(Swedish Mutant) Transgenic Mice
We wondered whether the increased HO inhibitory activ- similar to our previous observations (Dore´ et al., 1999a).
No protection occurs with the inactive isomer of PMAity elicited by FAD mutant APP would be evident in intact
organisms with such mutations. Recently transgenic (4a-PMA, 0.1 mM). Moreover, the protective effect of
PMA in wild-type cultures is blocked by the HO inhibitormice have been developed expressing APP with the
Swedish FAD mutation (Mo/Hu APP695swe; Borchelt et (Tin protoporphyrin-IX [SnPPIX], 5 mM). The combination
of diminished bilirubin levels and decreased HO activityal., 1996). We reasoned that if the mutant APP dimin-
ishes HO2 activity in the intact transgenic organism, in mutant-derived cultures implies a causal link. How-
ever, altered expression of biliverdin reductase mightthis should be evident as decreased bilirubin formation.
Using antibodies to detect bilirubin formation in mouse influence bilirubin levels. Western blot analysis indicates
no difference between biliverdin reductase expressionneuronal cultures, we previously found that stimulation
of protein kinase C activity by phorbol ester markedly between mutant and wild-type brains (data not shown).
We also examined hemin toxicity in primary cortical cul-augments HO2 activity and results in increased bilirubin
staining (Dore´ et al., 1999a). We utilized cortical cultures tures derived from nontransgenic and Mo/Hu APP695swe
transgenic mice. At all concentrations of hemin exam-made from E19 embryos of APP Swedish mutant or
nontransgenic mice and monitored bilirubin accumula- ined, cultures prepared from Mo/Hu APP695swe are
more susceptible to toxicity than wild-type cultures (Fig-tion in response to treatment with 0.1 mM phorbol myris-
Neuron
468
Figure 6. Phorbol Myristyl Acetate (PMA)
Augmentation of Bilirubin (BR) Is Abolished
in Familial Alzheimer’s Disease Swedish Mu-
tation (Mo/Hu APP695swe) Mouse Cortical
Cultures
Cultured cortical neurons from nontransgenic
(non-TG) and Mo/Hu APP695swe transgenic
mice (TG) were incubated with the antibody
against BR to assess BR accumulation with
and without PMA treatment.
(A) Photomicrograph of staining performed
without (Ctl) or with 0.1 mM PMA (1PMA).
(B) Graph representing the relative intensity
of bilirubin accumulation in non-TG and TG
mice without or with PMA (plus sign) treat-
ment. Results are mean of triplicate determi-
nations and the experiments were repeated
three times with similar results.
ures 7A and 7B). Conceivably, the greater toxicity in by increased HO activity following treatment with PMA
(Dore´ et al., 1999a). While PMA treatment decreasesMo/Hu APP695swe cultures might arise from some ef-
fect unrelated to inhibition of HO. Accordingly, we H2O2 toxicity in the nontransgenic cultures, PMA has
no effect on toxicity in the Mo/Hu APP695swe culturestreated Mo/Hu APP695swe and nontransgenic cultures
with 5 mM SnPPIX, a selective HO inhibitor when em- (Figure 7D). The HO inhibitor SnPPIX blocks the effect
of PMA in the nontransgenic cultures (Figure 7D). Weployed in mammalian tissues at 1–10 mM (Drummond
and Kappas, 1981; Yoshinaga et al., 1982; Zakhary et al., monitored expression of HO2, HO1 and APP by Western
blot (Figure 7E). Expression of APP is about 3-fold higher1996). SnPPIX treatment increases the hemin-mediated
toxicity in nontransgenic neuronal cultures but has no in the cultures from transgenic mice. HO2 and APP levels
are not influenced by hemin or H2O2 treatment, whileeffect in Mo/Hu APP695swe cultures. In the presence of
SnPPIX, the concentration-response relationship for he- these treatments do augment HO1 levels.
min is similar in Swedish mutant and wild-type cultures
(Figure 7B). These data strongly suggest that the greater Discussion
susceptibility of the Mo/Hu APP695swe cultures to he-
min toxicity reflects decreased HO activity. In other ex- In the present study, we have identified an interaction
between APP/APLP and HO. The protein–protein inter-periments, we examined the effect of Mo/Hu APP695swe
mutation on toxicity in response to H2O2. Cultures from actions have been established both by yeast two-hybrid
analysis and coimmunoprecipitation. The site of interac-Mo/Hu APP695swe transgenic mice are more suscepti-
ble to H2O2-mediated toxicity than nontransgenic cul- tion between these proteins appears to be in the lumen
of the endoplasmic reticulum (ER), as mutations in APPtures (Figure 7C). Previously, we demonstrated that H2O2
toxicity in hippocampal and cortical cultures is reduced that disrupt the lumenal ER localization prevent interac-
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Figure 7. Primary Cortical Neurons from Mo/
Hu APP695swe Transgenic Mice Display HO
Inhibition and Manifest Increased Cell Death
in Response to Stress
(A and B) After 6 days in culture, cortical neu-
ronal cultures from nontransgenic and Mo/
Hu APP695swe transgenic mice were prein-
cubated with or without SnPPIX (5 mM) for 2
hr and then exposed for 24 hr to different
concentrations of hemin.
(C and D) After 5 days culture, the cortical
cultures were pretreated with or without 0.1
mM of PMA for 24 hr and then exposed to
H2O2 for 24 hr. Cell survival was assayed by
MTT. Asterisk, p , 0.05; double asterisk, p ,
0.01 versus nontransgenic mice.
(E) Expression of HO1, HO2, and APP were
determined in 10 mg of cell extracts by immu-
noblot analysis using anti-HO1 (SPA895),
HO2 (SPA897), and APP (CT15) antibodies
after treatment with hemin and H2O2 for 6 hr.
Results are mean of triplicate determinations,
and the experiments were repeated three
times with similar results.
tions with HO, and HO2 itself is localized to the lumen conformation of APP may bring the acidic domain close
to the cell membrane facilitating interactions with HO.of the ER. HO has physiologic antioxidant properties
(Poss and Tonegawa, 1997b; Dennery et al., 1998; Ferris This hypothesis is supported by the finding that
APP695D305–590 has about the same HO inhibitory ac-et al., 1999), while generation by HO of intracellular free
iron might increase oxidative stress (Van Lenten et al., tivity as full-length APP695. Such a localization for the
acidic domain would bring it into juxtaposition with the1995). However, since the catalytic site of HO is facing
the lumenal side of the ER, free iron produced by HO transmembrane, carboxyl portion of APP, which con-
tains FAD mutations in the APP ectodomain. In this way,should be rapidly released outside of cells.
In cells cotransfected with APP and HO isoforms, we the Swedish and Dutch mutations might influence the
ability of the acidic domain to bind HO. The London-failed to find any effect of HO1 or HO2 on the processing
of APP695 and APP770 into Ab peptides. However, we type mutation involves the transmembrane domain of
APP. Since both HO and APP are membrane-boundhave found a striking inhibitory effect of APP on HO
activity in lysates and intact cells. FAD mutant forms proteins, transmembrane interactions between the two
proteins might be stabilized due to the mutant APP se-of APP elicit substantially greater inhibition of HO and
augmentation of hemin toxicity than wild-type APP. quences.
Though aberrations in APP processing certainly are as-How might HO and APP be juxtaposed to facilitate
HO inhibition? HO binds APP near the carboxyl terminus sociated with Alzheimer’s disease, mechanisms whereby
neurotoxic insults originate have not been definitivelyof HO and adjacent to the catalytic domain, allowing
APP binding to inhibit enzyme activity. HO binds to the established. Because Ab peptide is a component of the
amyloid plaques that accumulate in the disease, it isacidic domain of APP located about one-third of the
distance from the N-terminal to the C-terminal portion. reasonable to assume that Ab is a neurotoxic culprit.
Indeed, Ab42 peptide is neurotoxic to cultured neuronsSince the C-terminal portion of the protein is attached
to the membrane, this acidic domain would be distant (Yankner, 1996). However, most lines of APP transgenic
mice with high levels of amyloid plaques do not experi-from the membrane if it were fully extended. A folded
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ence major neural degeneration (Games et al., 1995; Sporadic AD may reflect multiple etiologies and
Hsiao et al., 1996), though recently some lines have pathogenic mechanisms. Free radical induced oxidative
displayed such alterations (Calhoun et al., 1998). stress has been implicated in the pathophysiology of
To ascertain whether the inhibition of HO activity by sporadic AD (Markesbery, 1997). Increased oxidative
mutant APP is physiologically relevant, we stained corti- damage (Smith et al., 1996; Gabbita et al., 1998), iron
cal neuronal cultures from APP695swe transgenic mice accumulation (Good et al., 1992; Loeffler et al., 1995;
for bilirubin, which reflects HO activity. The phorbol ester Lovell et al., 1998), and HO1 induction (Smith et al., 1994;
stimulation of bilirubin accumulation in nontransgenic Schipper et al., 1995) have been reported in sporadic
litter cultures is abolished in cultures from APP965swe AD brain. These phenotypes resemble those from APP
transgenic littermates. These findings parallel the lack transgenic mice and HO-deficient mice. Thus, HO may
of neuroprotection by PMA in cultures from the mutant modulate oxidative damage in sporadic AD. Conceiv-
mice. Neuroprotection by PMA is due to activation of ably, decreased neuroprotection associated with inhib-
HO2, as the neuroprotection is lost in cultures from mice ited HO activity facilitates neurotoxicity elicited by Ab
with deletion of HO2 as observed previously (Dore´ et peptides. If HO plays a role in neurotoxicity associated
al., 1999a) and replicated here. Moreover, nanomolar with various APP forms, then drugs that block interac-
bilirubin concentrations applied to neuronal cultures tions of APP and HO might be therapeutic. Additionally,
produce neuroprotection similar to the influences of such agents would facilitate our understanding of physi-
PMA. The concentrations of bilirubin that are neuropro- ologic and pathophysiologic implications of HO-APP as-
tectant correspond to physiologic brain levels in rodents sociations.
(Hansen et al., 1999). Together these findings indicate
that the failure of PMA to provide neuroprotection to Experimental Procedures
mutant cultures is due to the inhibition of the generation
Reagents and Cell Linesof bilirubin by HO2 in the mutant cultures. Basal bilirubin
Rabbit anti-HO1 (SPA896), anti-HO2 (SPA897, OSA200), anti-Cal-staining in transgenic mice is close to background and
nexin (SPA870) antiserum, and an anti-KDEL (Grp78) monoclonal
appears to be the same as in nontransgenic mice. This antibody (SPA827) were purchased from StressGen (Victoria, Can-
suggests that the very low basal HO2 activity is not ada). Anti-(His)6 and anti-APP/APLP (22C11) monoclonal antibodies
involved in neuroprotection but presumably in the turn- were purchased from Invitrogen (Carlsbad, CA) and Boehringer
Mannheim (Indianapolis, IN), respectively. Other anti-APP antibod-over of heme, with HO2 participating in neuroprotection
ies (CT15) have been described previously (Thinakaran et al., 1995).only following its activation by protein kinase C or other
HEK293 cell lines stably expressing human CPR and human HO1stimuli.
(HEK 293/CPR-HO1) or human HO2 (293/CPR-HO2) have been de-Our findings indicate that HO inhibition may be neuro-
scribed previously (Dore´ et al., 1999a). These cell lines were cultured
toxic by diminishing the formation of bilirubin and/or in DMEM supplemented with 10% FCS, 500 mg/ml of G418, and
leading to less iron efflux from cells. HO catalytic activity 500 mg/ml of Zeocin (Sigma, St. Louis, MO). (Gly)5(His)6 tag was
gives rise to bilirubin, a known antioxidant (Stocker et introduced on the C terminus of APLP1 by PCR.
al., 1987). H2O2 and hemin toxicities are markedly aug-
Yeast Two-Hybrid Methodsmented in cultures from HO1- and HO2-deficient mice
Two-hybrid screening and the construction of the parent vectorsand low nanomolar concentrations of bilirubin reverse
pPC97 and pPC86 were as described (Chevray and Nathans, 1992).this toxicity. Reversal of the toxicity by phorbol esters
Plasmid pPC97-HO2C was prepared by the insertion of an HO2
appears to involve stimulation of PKC to activate HO2 PCR product corresponding to amino acids 169–296 of rat HO2
(Dore´ et al., 1999a). Recent evidence also indicates a (Rotenberg and Maines, 1990) into the SalI and BglII sites of pPC97,
role for HO in facilitating the transport of iron out of resulting in an open reading frame encoding a GAL4 BD-HO2 fusion
cells. Thus, several organs of HO-deficient mice are protein. The HO2 fragment was constructed by PCR using the fol-
lowing primers: 59-GGATCCGTCGACCGTGGCTCAGCGGGCAoverloaded with iron, while serum iron levels in these
CTA-39 (coding strand) and 59-GGATCCAGATCTCACTGCAGGCmice are reduced (Poss and Tonegawa, 1997a; Dennery
TAGGCTTCC-39 (noncoding strand). A rat cortex/hippocampalet al., 1998). Transfection of HO1 or HO2 into cells aug-
cDNA library in pPC86 was amplified once in DH10B (GIBCO–BRL,
ments iron efflux, which is diminished in cells from HO1- Gaithersburg, MD) and transformed into yeast Y190 containing the
deficient animals (Ferris et al., 1999). pPC97-HO2C (Walensky et al., 1998). pPC86-C105 was identified
Evidence in favor of the notion that HO inhibition is as a 1.3 kb clone that activated LacZ transcription and conferred
histidine prototrophy in the presence of pPC97-HO2C. Truncatedrelevant to the neurotoxicity of Alzheimer’s disease in-
APLP1 fragments comprising amino acids 68–436 and 68–385 werecludes the greater neurotoxicity elicited by the FAD mu-
generated by restriction of pPC86-C105 with NcoI–NotI and PflMI–tant forms of APP. Also, in primary cultures from embry-
NotI, respectively, followed by klenow filling of the ends and self-onic cerebral cortex of mice with transgenic expression
ligation. Other truncated APLP1 fragments were prepared by PCR.
of the Swedish FAD mutant APP, both hemin and H2O2 Specificity of the interaction was confirmed for HO2 and APLP-1,
toxicity is greater than in nontransgenic cultures. APP and no activation was observed with HO2 and the vector only and
transgenic mice display neural oxidative stress as well the vector only with APLP-1. In addition, we did not detect activation
with HO2 and PIN or with GAPDH and APLP-1.as a striking induction of HO1 activity in the brain (Pap-
polla et al., 1998; Smith et al., 1998). These animals
Immunoprecipitationsevince higher susceptibility to ischemic brain damage
Human HO1, human HO2, human APP695, human APP770, mouse(Zhang et al., 1997). Similarly, neural damage following
APLP1, and mouse APLP2-763 cDNA were subcloned into pRK5middle cerebral artery occlusion is markedly accentu-
under the transcriptional control of the cytomegalovirus (CMV) im-
ated in HO2-deficient mice (Dore´ et al., 1999b). In- mediate-early promoter-enhancer (Schall et al., 1990). HEK293 cells
creased oxidative stress was also reported in cultured on 10 cm dishes were transfected with 10 mg of the APP constructs
fetal Down’s syndrome cortical neurons (Busciglio and alone or in combination with 5 mg of the HO1 or HO2 constructs by
the calcium phosphate precipitation method (Ausubel et al., 1994).Yankner, 1995; Sawa et al., 1997).
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After 40 hr, cells were solubilized with 500 ml of lysis buffer (50 mM Boston, MA) as described (Zakhary et al., 1997) with slight modifica-
tions. Briefly, the assay was performed in 250 ml of 50 mM HEPES-Tris-HCl [pH 7.4], 150 mM NaCl, 0.5% Triton X-100) on ice for 30
min and then cleared by centrifugation. For immunoprecipitation, NaOH [pH 7.4], 1 mM EDTA, 10% glycerol, 0.2 mM NADPH, and 0.6
mM [55Fe]hemin (30,000 cpm). After 5 min at 378C, the reaction was20 ml aliquots of the cleared lysates were diluted to 100 ml with
dilution buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl) and incubated stopped with addition of 10 mM of SnPPIX. The reaction mixture
was added to Dowex AG1X-8 (Bio-Rad Lab, Hercules, CA), and freewith 1 ml of the anti-HO1 antibody (SPA896) or the anti-HO2 antibody
(OSA200). The mixture was incubated at 48C for 1 hr, mixed with 20 iron produced was eluted with 50 mM HEPES-NaOH [pH 7.4], 1 mM
EDTA, and 1 M NaCl. In routine assays, total activity correspondsml of a 1:1 slurry of protein A–agarose (Calbiochem, La Jolla, CA),
and incubated for another 30 min at 48C. The beads were washed to about 4000 cpm, while background is less than 700 cpm.
twice with wash buffer A (50 mM Tris-HCl [pH 7.4], 300 mM NaCl,
0.1% Triton X-100), twice with wash buffer B (50 mM Tris-HCl [pH Immunocytochemistry for Bilirubin
7.4], 150 mM NaCl, 0.1% Triton X-100), and then proteins were After primary neuronal cultures were incubated for 24 hr with and
eluted in 50 ml of SDS–PAGE sample buffer by boiling. The immuno- without PMA (0.1 mM), cells were rinsed with ice-cold PBS and fixed
precipitates were fractionated on 4%–15% SDS–PAGE gels, trans- with 6% EDC (Pierce) at 48C for 2 hr as described before (Dore´ et
ferred to nitrocellulose membranes, and immunoblotted with an al., 1999a). Cells were washed with PBS, incubated with 0.1% Triton
anti-APP/APLP (22C11) or anti-His antibodies. Immunoblots were X-100 for 15 min at room temperature, and washed with PBS. Cells
visualized using an enhanced chemiluminescence system (ECL, were then preincubated for 1 hr with 4% NGS in PBS followed by
Amersham, Arlington Heights, IL). For immunoprecipitation from rat incubation with anti-bilirubin (BR) antibody in 2% NGS for 2 hr at
brain, one brain was homogenized in 3 ml of homogenization buffer room temperature. Cells were then washed and incubated with the
(Tris-HCl [pH 7.4], 150 mM NaCl, and 10% glycerol) and centrifuged secondary antibody and developed.
at 100,000 3 g for 30 min. The pellets were solubilized in 3 ml of
homogenization buffer containing 0.5% Triton X-100 and recentri- Hemin Toxicity Assay
fuged at 100,000 3 g for 30 min. The supernatant (100 ml) was HEK293/CPR-HO1 or 293/CPR-HO2 cells were transfected with vari-
diluted 2-fold with homogenization buffer and incubated with 30 ml ous concentrations of APP constructs by electroporation and then
of protein G–agarose that was cross-linked to 20 ml of an anti-HO2 plated onto 6-well dishes. Total plasmid concentration was normal-
antibody (OSA200) or the anti-Calnexin antibody (SPA 870) for 60 ized with the pRK5 parent vector to 2 mg. After 5 hr incubation,
min at 48C (Harrow and Lane, 1988). The immunoprecipitates were hemin was added into the culture medium. After another 24 hr, cells
then washed five times with wash buffer B and eluted in 50 ml of were collected and cytotoxicity was determined by Trypan blue
SDS–PAGE sample buffer. exclusion using a hematocytometer. In some experiments, cells
were cotransfected with APP constructs and a LacZ-pRK5 construct
so that b-gal enzymatic activity could be used for a quantitativeSubcellular Fractionation
and rapid determination of hemin toxicity. After 12 hr of incubationSubcellular fractionation of the mouse neuroblastoma N2a cell lines
with hemin, cells were harvested and disrupted in 0.2 M Tris-HCl(maintained in 50% DMEM and 50% OptiMEM [Life Technologies,
[pH 8.0]. Then, b-gal activity was determined by a b-gal assay kitRockville, MD] supplemented with 5% FBS) was performed as de-
using o-Nitrophenyl-b-D-galactopyranoside as a substrate (In-scribed before (Kim et al., 2000).
vitrogen).
Immunofluorescence
Primary Cultures of Neuronal CellsHEK293/CPR-HO2 cells grown on lab chambers were washed with
Mo/Hu APP695swe transgenic mice have been described previouslyPBS and fixed with 2% paraformaldehyde-PBS for 20 min. The lab
(Borchelt et al., 1996). Cortical neuronal cells were isolated fromchambers were washed with PBS and incubated with permeabiliza-
litters of heterozygous Mo/Hu APP695swe transgenic or nontrans-tion buffer (10 mM PIPES-NaOH [pH 6.8], 0.3 M sucrose, 0.1 M KCl,
genic pups at embryonic day 18 as described (Dore´ et al., 1999a).2.5 mM MgCl2, and 1 mM EDTA) with or without 5 mg/ml digitonin
For hemin toxicity assay, neurons were plated onto poly-D-lysine-for 15 min on ice (Otto and Smith, 1994). The coverslips were then
and laminin-coated 24-well plates at a density of 0.75 3 106 cells/washed with PBS and blocked in blocking solution (PBS, 1% BSA,
well in Neurobasal medium supplemented with B27. After 6 days inand 1% normal goat serum). Subsequent washings and primary
culture, cells were incubated in fresh medium with or without SnPPIXantibody (22C11 and SPA897) incubations were conducted in
(5 mM) for 2 hr, and then hemin was added into the culture medium.blocking buffer with or without 0.2% saponin for 5 hr at 48C. Then,
Cell survival was determined 24 hr later using 3-(4,5-dimethylthiazol-cells were stained with a FITC-labeled goat anti-rabbit IgG antibody
2yl)2,5-diphenyl tetrazolium bromide (MTT) assay (Dore´ et al., 1997)or a Texas red–labeled goat anti-mouse IgG antibody (Jackson Lab).
or a LDH cytotoxicity detection kit (Boehringer Mannheim). For H2O2Rat primary cortical neuron cultures were prepared as described
toxicity assay, neurons were placed in the N2 supplement HEPES-(Dore´ et al., 1997). Cells were fixed with 4% paraformaldehyde and
buffered high-glucose Neurobasal medium at day 5. Cells werepermeabilized with 0.1% Triton X-100. Immunofluorescent staining
treated with or without PMA for 24 hr and then exposed to H2O2 forwas conducted using an anti-HO2 antiserum (SPA897) or anti-APP/
24 hr.APLP2 antibody (22C11) as described above.
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